Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238939 · ClinicalTrials.gov registry record · Phase 1
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
A Phase 1 study, sponsored by Nippon Kayaku Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01238939 is a Phase 1 study that has completed, run by Nippon Kayaku Co.. The registered enrollment target is 35 participants.
The verdict
NCT01238939, a Phase 1 study, has completed, sponsored by Nippon Kayaku Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.
Interventions
- DRUG NK012 and 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01238939
The ClinicalTrials.gov registry entry for NCT01238939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nippon Kayaku Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK012 and 5-FU is the first listed.
NCT01238939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01238939 about?
NCT01238939 is a clinical study titled "Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer". The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.
What is the current status of trial NCT01238939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2010-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01238939?
The interventions under investigation include: NK012 and 5-FU (DRUG).
Who is sponsoring clinical trial NCT01238939?
This trial is sponsored by Nippon Kayaku Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.